Cipla has elevated Samina Vaziralli, part of the firm's founding family, to its board, amid a series of top level exits that have rocked the company over the recent past.
Cipla has elevated Samina Vaziralli, part of the firm's founding family, to its board, amid a series of top level exits that have rocked the company over the recent past.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
